| | |

Avelumab May Offer a Second-Line Option for Recurrent Mesothelioma

ByAlex Strauss

recurrent mesothelioma treatmentPeople with recurrent mesothelioma may get another chance at treatment with the immunotherapy drug avelumab.

Malignant mesothelioma is highly resistant to standard cancer therapies. That means that the asbestos cancer usually comes back, or recurs, even after treatment.

The most common treatment for mesothelioma is chemotherapy with Alimta. Alimta is the only drug approved specifically for mesothelioma. Patients with recurrent mesothelioma often have several rounds of chemotherapy with Alimta.

But once the standard mesothelioma treatments stop working, patients do not have many options.

Now a new study suggests that some cases of recurrent mesothelioma that stop responding to Alimta may respond to avelumab.  

Considering Avelumab for Recurrent Mesothelioma

Bavencio is the brand name for avelumab. It is a type of immunotherapy drug called a monoclonal antibody. Bavencio targets a protein called programmed death-ligand 1 (PD-L1).

PD-L1 helps mesothelioma cells “hide” from the immune system.

The FDA originally approved Bavencio to treat non-small-cell lung cancer. It has since been approved to treat stomach cancer and a certain kind of skin cancer, too.

The National Cancer Institute ran the new study on Bavencio for mesothelioma. It included patients with recurrent mesothelioma from 25 sites in three countries. They were all diagnosed between September 2014 and July 2015.

Fifty-three patients received Bavencio. Thirty-eight percent of them already had three or more other kinds of mesothelioma treatments.

They got 10 mg/kg of Bavencio every two weeks until their mesothelioma came back or until they got too sick to continue.

Avelumab Deemed Safe and Effective as Second-Line Treatment

Researchers monitored the recurrent mesothelioma patients in this study for a median of two years.

Sixty-seven percent of patients responded well to Bavencio. In one patient, the drug wiped out their mesothelioma tumor. Four other patients saw their tumors shrink.

For fifty-eight percent, their recurrent mesothelioma stopped growing. It took a median of four months for mesothelioma tumors to start growing again after treatment with Bavencio.

Forty-three percent of patients were still alive a year after treatment.

Only 8 patients had a serious side effect either from the treatment or from its impact on their immune system. There were no treatment-related deaths.

“Avelumab showed durable antitumor activity and disease control with an acceptable safety profile in a heavily pretreated cohort of patients with mesothelioma,” concludes the report.

About 3,000 people contract mesothelioma in the US each year. Most do not live longer than a year.

Source:

Hassan, R, et al, “Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial”, January, 3, 2019, JAMA Oncology, Epub ahead of print, https://jamanetwork.com/journals/jamaoncology/fullarticle/2719756

 

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…